Back

Optum Health Education

  • Anemia, Sickle Cell
  • Genetic Therapy
  • Stem Cell Transplantation

New Horizons in Sickle Cell Disease Treatment: Clinician and Patient Perspectives

This activity will provide a comprehensive overview of the latest advancements in sickle cell disease (SCD) treatment, focusing on gene therapy and CRISPR gene editing, pain management and the utilization of stem cell transplantation. It will also highlight recent US Food and Drug Administration approvals of cell-based gene therapies for SCD, these therapies mechanisms of action and their clinical impact and address practical considerations for implementing these treatments and patient selection parameters.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 creditPsychologyUp to 1 creditSocial WorkUp to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • Credit · Up to 1 credit
  • Commercial Support
  • Released
    Dec 9, 2024
  • Last day to claim credit
    Dec 10, 2027 1 year left